Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02916537 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057
A Phase 1 study of Prostate Cancer, sponsored by Cancer Targeted Technology.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02916537: Completed Phase 1 study of Prostate Cancer, sponsored by Cancer Targeted Technology.
NCT02916537 is a Phase 1 study of Prostate Cancer that has completed, run by Cancer Targeted Technology. The registered enrollment target is 20 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02916537, a Phase 1 study of Prostate Cancer, has completed, sponsored by Cancer Targeted Technology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test a novel diagnostic Positron Emission Tomography (PET) imaging agent for safety and biodistribution. The agent binds Prostate Specific Membrane Antigen (PSMA) and is designed to detect prostate tumors.
Conditions Studied
Interventions
- PROCEDURE Prostatectomy
- DRUG CTT1057
Study Locations (1)
California
- University of California San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-09 |
| Est. Completion | 2017-08-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02916537
The ClinicalTrials.gov registry entry for NCT02916537 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Cancer Targeted Technology, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Prostatectomy is the first listed.
NCT02916537 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02916537 about?
NCT02916537 is a clinical study titled "A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057". The purpose of this study is to test a novel diagnostic Positron Emission Tomography (PET) imaging agent for safety and biodistribution. The agent binds Prostate Specific Membrane Antigen (PSMA) and is designed to detect prostate tumors.
What is the current status of trial NCT02916537?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2016-09. Estimated completion is 2017-08-28.
What conditions does trial NCT02916537 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02916537?
The interventions under investigation include: Prostatectomy (PROCEDURE), CTT1057 (DRUG).
Who is sponsoring clinical trial NCT02916537?
This trial is sponsored by Cancer Targeted Technology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02916537 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.